Skip to main content

Table 1 Description of the dataset

From: Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease

     

AD (SORL1)

  

Control

FTLD

AD (SORL1 WT)

AD (SORL1 nTD)

AD (SORL1 TD)

AD (SORL1 nTD + TD)

N

 

30

34

40

31

16

47

Age at LP

years, mean (min-max)

63 (40–75)

65 (45–77)

63 (51–76)

65 (52–76)

61 (46–69)

64 (46–76)

AAO

years, mean (min-max)

  

60 (48–72)

60 (49–73)

57 (44–65)

59 (44–73)

Time AA0-LP

years, mean (min-max)

  

3.9 (0.6–13.9)

4.7 (0.3–10.1)

3.7 (1.3–9.8)

4.4 (0.3–10.1)

Gender

Male N (%)

15 (50.00%)

18 (52.94%)

16 (40.00%)

9 (29.03%)

6 (37.50)

15 (31.91 %)

 

Female N (%)

15 (50.00%)

16 (47.06%)

24 (60.00%)

22 (70.97%)

10 (62.50)

32 (68.09%)

APOE

ε2/ε2 N (%)

  

0

0

0

0

 

ε2/ε3 N (%)

  

1 (2.50%)

1 (3.23%)

0

1 (2.13%)

 

ε2/ε4 N (%)

  

0

2 (6.45%)

0

2 (4.25%)

 

ε3/ε3 N (%)

  

16 (40.00%)

9 (29.03%)

8 (50.00%)

17 (36.17%)

 

ε3/ε4 N (%)

  

16 (40.00%)

15 (48.39%)

7 (43.75%)

22 (46.81%)

 

ε4/ε4 N (%)

  

7 (17.50%)

4 (12.90%)

1 (6.25%)

5 (10.64%)

  1. Mean (min-max) means that the variable is described by the mean (minimum-maximum)
  2. N (%) means that the variable is described by the number (and percentage) of individuals in each category
  3. AAO and APOE status are available for AD patients only
  4. LP Lumbar Puncture, AAO Age At Onset, FTLD Frontotemporal Lobar Degeneration, AD Alzheimer Disease, TD Trafficking Defective, nTD not Trafficking Defective